AI assistant
BeOne Medicines Ltd. — Director's Dealing 2025
Apr 3, 2025
30073_dirs_2025-04-03_910744ca-9d75-41e6-9bd2-6541622074ee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2025-04-01
Reporting Person: Wu Xiaobin (President, COO & GM China)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-01 | American Depositary Shares | M | 16477 | $119.96 | Acquired | 16477 | Direct |
| 2025-04-01 | American Depositary Shares | M | 35444 | $174.43 | Acquired | 51921 | Direct |
| 2025-04-01 | American Depositary Shares | S | 28253 | $280.3114 | Disposed | 23668 | Direct |
| 2025-04-01 | American Depositary Shares | S | 6364 | $281.6736 | Disposed | 17304 | Direct |
| 2025-04-01 | American Depositary Shares | S | 12221 | $282.7625 | Disposed | 5083 | Direct |
| 2025-04-01 | American Depositary Shares | S | 5083 | $283.7932 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-01 | Share Option (Right to Buy) | $9.23 | M | 214201 | Disposed | 2029-06-04 | Ordinary Shares (214201) | Direct |
| 2025-04-01 | Share Option (Right to Buy) | $13.42 | M | 460772 | Disposed | 2030-06-16 | Ordinary Shares (460772) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 1176068 | Direct |
| American Depositary Shares | 12365 | Direct |
| American Depositary Shares | 4000 | Indirect |
Footnotes
F1: Includes 858 ordinary shares acquired pursuant to the Company's Fourth Amended and Restated 2018 Employee Share Purchase Plan.
F2: Each American Depositary Share represents 13 Ordinary Shares.
F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.00 to $280.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.01 to $282.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.03 to $283.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.12 to $284.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F8: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.
F9: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.
F10: These securities vest over a four-year period as follows: 25% on June 17, 2021 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.